GMDA NASDAQ
Jerusalem 91340
IL
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicelâa specialized cell therapyâhas successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| MOCH KENNETH I | A-Award | 200,000 | — | 2024-01-31 |
| WILLS STEPHEN T | A-Award | 200,000 | — | 2024-01-31 |
| Tomasello Shawn | A-Award | 200,000 | — | 2024-01-31 |
| ADAMS JULIAN | A-Award | 200,000 | — | 2024-01-31 |
| Simantov Ronit | A-Award | 480,319 | — | 2024-01-31 |